




or pharmaceutically acceptable salts and isomers thereof.

11. A pharmaceutical composition including a compound according to claim 1 and a pharmaceutically acceptable diluent, excipient or carrier.

~~12. A method of treatment of diabetes in a mammal that is treated by inhibition of 11 β HSD1, the method comprising administering an effective amount of a compound according to claim 1.~~

~~13. A method according to claim 12 wherein the diabetes is type II diabetes.~~

~~14. The method of claim 12, wherein the compound is administered in combination with an adjuvant.~~

~~15. The method of claim 14, wherein the adjuvant is selected from the group consisting of dipeptidyl peptidase-IV (DP-IV) inhibitors; (b) insulin sensitizing agents; (c) insulin and insulin mimetics; (d) sulfonylureas and other insulin secretagogues; (e) alpha-glucosidase inhibitors; (f) GLP-1, GLP-1 analogs, and GLP-1 receptor agonists; and combinations thereof.~~

~~16. The method of claim 15, wherein the insulin sensitizing agents are selected from the group consisting of (i) PPAR-gamma-agonists, (ii) PPAR-alpha-agonists, (iii) PPAR-alpha/gamma dual agonists, (iv) biguanides, and combinations thereof.~~